Form 4: PLUS THERAPEUTICS CEO Vesting RSU Grant

PLUS THERAPEUTICS CEO Marc H. Hedrick reported the vesting of 159,681 Restricted Stock Units, converting them into common stock.

Summary

• Marc H. Hedrick, Chief Executive Officer and Director of PLUS THERAPEUTICS, INC. (PSTV), reported a change in beneficial ownership.
• On October 1, 2025, 159,681 Restricted Stock Units (RSUs) vested.
• Each RSU represents a contingent right to receive one share of the issuer's Common Stock.
• The vesting occurred at a price of $0 per unit, converting the RSUs into common stock.
• Following this transaction, Hedrick beneficially owns 180,106 shares of Common Stock directly.
• He also holds 1,756,487 derivative securities in the form of Restricted Stock Units.
• The RSU grant vests in twelve substantially equal quarterly installments, commencing on October 1, 2025.

Sentiment

Score: 6

Explanation: The event is a routine, pre-scheduled vesting of equity compensation, which is generally neutral but slightly positive as it increases direct insider ownership, aligning management interests with shareholders.

Positives

• Increased direct ownership by the CEO, aligning management interests with shareholders.
• The vesting of RSUs is a planned compensation event, indicating continued commitment from the CEO.

Negatives

• No direct negative implications from this routine vesting event.

Future Outlook

The remaining Restricted Stock Units are scheduled to vest in eleven additional substantially equal quarterly installments following the initial vesting on October 1, 2025.

Industry Context

This filing represents a routine insider transaction, specifically the vesting of equity compensation, which is a common practice across industries to align executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholders due to higher direct stock ownership.
• Management: The vesting represents a component of the CEO's compensation package, reinforcing retention.

Next Steps

• Future quarterly installments of the RSU grant will continue to vest as per the established schedule.

Key Dates

Recommendation

This is a routine insider transaction related to the vesting of equity compensation and does not indicate a change in the company's fundamental business operations, financial health, or strategic outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

PSTV, PLUS THERAPEUTICS, Form 4, RSU, Vesting, Insider Transaction, Marc H. Hedrick, Common Stock